Established Cardiovascular Disease: Pediatric vs. Adult Differences

What Counts as "Established" Cardiovascular Disease in Each Age Group

Established CVD means documented structural or functional cardiac pathology, not simply elevated risk factors. In adults, established CVD is defined by prior myocardial infarction, coronary revascularization, stroke, peripheral artery disease, or confirmed atherosclerotic plaque burden on imaging. In children, the definition shifts: established CVD most often means a confirmed congenital heart defect, an inherited cardiomyopathy, Kawasaki disease with coronary artery aneurysms, or a rheumatic heart lesion.

The American Heart Association's 2019 cardiovascular disease statistics report estimated that 121.5 million American adults carry at least one form of CVD, with coronary heart disease accounting for 18.2 million of those cases [1]. Pediatric prevalence figures are smaller in absolute numbers but carry outsized lifetime impact because disease begins at or before birth.

Why the Definition Matters Clinically

Misapplying adult CVD criteria to a child risks either over-treating a child whose anatomy is still maturing or, more dangerously, under-treating a teenager with familial hypercholesterolaemia (FH) whose LDL-C has already initiated plaque formation. Autopsy data from the Bogalusa Heart Study confirmed coronary atherosclerosis in individuals aged 2 to 39, with lesion extent directly correlated to antemortem LDL-C levels [2].

Shared Pathophysiology Across Age Groups

Despite different dominant etiologies, inflammation, oxidative stress, and endothelial dysfunction contribute to disease progression in both age groups. A 2022 meta-analysis in the Journal of the American College of Cardiology (N=44 pediatric cohort studies) found elevated high-sensitivity C-reactive protein in children with congenital heart disease and in obese youth with early atherosclerotic markers [3].

Etiology: Structural Defects vs. Acquired Atherosclerosis

The single sharpest divide between pediatric and adult established CVD is cause. Pediatric CVD is predominantly structural and genetic; adult CVD is predominantly acquired and lifestyle-mediated, though genetic predisposition (familial hypercholesterolaemia, hypertrophic cardiomyopathy) bridges both worlds.

Congenital Heart Disease as the Pediatric Prototype

Congenital heart disease (CHD) affects approximately 8 to 9 per 1,000 live births, according to the CDC [4]. Ventricular septal defect is the most common isolated lesion (32% of CHD), followed by atrial septal defect (13%) and pulmonary stenosis (8%). Critical CHD requiring intervention in the first year of life occurs in roughly 25% of all CHD cases.

Genetic syndromes account for about 20% of CHD diagnoses. Trisomy 21 carries a 40 to 50% rate of congenital cardiac defects, most commonly atrioventricular septal defect. Turner syndrome (45,X) is associated with bicuspid aortic valve and coarctation of the aorta in 30 to 50% of affected individuals [5].

Atherosclerosis as the Adult Prototype

Adult established CVD centers on atherosclerosis, a process that begins silently in the second and third decades of life. The PDAY study (Pathobiological Determinants of Atherosclerosis in Youth, N=2,876 autopsies of individuals aged 15 to 34) demonstrated that raised coronary lesions were present in 2% of males aged 15 to 19 and increased to 20% of males aged 30 to 34 [6]. By the time a 55-year-old presents with an acute coronary syndrome, the culprit plaque has likely been developing for 20 to 30 years.

Kawasaki Disease: A Pediatric Cause of Acquired Coronary Disease

Kawasaki disease (KD) deserves specific mention because it produces acquired coronary artery aneurysms in children aged 6 months to 5 years. Without treatment, roughly 25% of children with KD develop coronary aneurysms; high-dose intravenous immunoglobulin (IVIG, 2 g/kg) reduces that rate to under 5% [7]. Adults who had KD as children represent a growing subgroup with established coronary disease that resembles atherosclerotic CAD on angiography but has a distinct pathophysiology.

Clinical Presentation

Children rarely present with chest pain as the dominant symptom of established CVD. Adult presentations are more classical: chest pressure, dyspnea on exertion, or sudden cardiac arrest in the setting of known risk factors.

Pediatric Presentation Patterns

Neonates with critical CHD present with cyanosis, respiratory distress, and poor feeding within hours to days of birth, often after the ductus arteriosus begins to close. Older children with cardiomyopathy may present with exercise intolerance, syncope, or an incidental murmur. A 2021 AHA Scientific Statement on hypertrophic cardiomyopathy (HCM) in pediatric patients noted that sudden cardiac death may be the first clinical manifestation in a meaningful minority of affected adolescents, making screening in first-degree relatives non-negotiable [8].

Adult Presentation Patterns

Adults with established atherosclerotic CVD present across a spectrum from asymptomatic (detected on stress testing or CT coronary angiography) to acute STEMI. The Global Burden of Disease 2019 study attributed 18.6 million deaths worldwide to CVD, with ischemic heart disease responsible for 9.14 million of those deaths [9]. Angina pectoris is the most common symptomatic presentation, affecting an estimated 9.8 million U.S. Adults.

Atypical presentations are more common in women and in people with diabetes: nausea, jaw pain, or unexplained fatigue may be the only symptoms of an evolving myocardial infarction.

Diagnostics: Age-Specific Tools and Thresholds

Adult CVD diagnostics lean heavily on electrocardiography, coronary CT angiography, and invasive catheterization. Pediatric diagnostics place echocardiography at the center, with cardiac MRI and genetic testing playing larger roles than in adult practice.

Echocardiography in Children

Two-dimensional echocardiography with Doppler remains the first-line diagnostic for all suspected pediatric cardiac disease. It defines anatomy, quantifies intracardiac pressures, and tracks ventricular function serially. The American Society of Echocardiography's pediatric guidelines specify normative z-score tables adjusted for body surface area, because a left ventricular end-diastolic dimension of 45 mm is normal in an adult but severely dilated in a 4-year-old [10].

CT Coronary Angiography and Calcium Scoring in Adults

For adults, coronary artery calcium (CAC) scoring adds prognostic information beyond traditional risk factors. A CAC score of zero in a low-to-intermediate risk adult confers a 10-year major adverse cardiovascular event rate under 1%, allowing deferral of statin therapy in select patients. A CAC score above 300 Agatston units reclassifies the patient to high risk regardless of calculated pooled cohort equation score [11].

Pediatric CAC scoring is not routinely performed because calcified plaque is rare before age 30 except in extreme phenotypes such as homozygous familial hypercholesterolaemia (HoFH).

Genetic Testing

Genetic testing is standard in pediatric practice for HCM (MYH7, MYBPC3), long-QT syndrome (KCNQ1, KCNH2, SCN5A), and CHD associated with syndromes. In adults, cascade genetic testing for FH (LDLR, APOB, PCSK9 variants) is increasingly recommended by the American College of Cardiology when LDL-C exceeds 190 mg/dL [12].

Pharmacological Treatment Differences

Drug selection, dosing, and monitoring intervals differ substantially between children and adults with established CVD, driven by pharmacokinetics, developmental physiology, and a historically thinner evidence base in pediatric trials.

Statins

In adults with established CVD, high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily) is a Class I recommendation from the ACC/AHA 2019 guidelines, targeting at least a 50% reduction in LDL-C [12]. The Cholesterol Treatment Trialists' Collaboration meta-analysis (N=174,149) showed each 1 mmol/L reduction in LDL-C reduces major vascular events by 22% [13].

For children with heterozygous FH, the ACC/AHA and European Atherosclerosis Society recommend statin initiation at age 8 to 10, with atorvastatin or rosuvastatin at the lowest effective dose, titrated to an LDL-C below 130 mg/dL (or below 100 mg/dL if additional risk factors are present) [14]. Liver enzyme monitoring every 3 to 6 months is standard during dose titration in pediatric patients.

Antiplatelet Therapy

Aspirin 75 to 100 mg daily is a Class I recommendation for adults with established atherosclerotic CVD [12]. Dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor such as ticagrelor 90 mg twice daily or clopidogrel 75 mg daily) is standard for 12 months after acute coronary syndrome or percutaneous coronary intervention [15].

In children, aspirin is used in Kawasaki disease (80 to 100 mg/kg/day during the acute febrile phase, then 3 to 5 mg/kg/day for 6 to 8 weeks or indefinitely if coronary aneurysms persist) and in children with mechanical heart valves or systemic-to-pulmonary shunts. Ticagrelor and clopidogrel lack strong pediatric pharmacokinetic data at standard adult doses [7].

Beta-Blockers and ACE Inhibitors

Adults post-MI receive metoprolol succinate or carvedilol (beta-blockers) and lisinopril or ramipril (ACE inhibitors) as guideline-directed medical therapy. The SAVE trial (N=2,231) established that captopril after anterior MI reduced cardiovascular mortality by 21% over 3.5 years [16].

Children with dilated cardiomyopathy receive carvedilol or enalapril, but pediatric dosing is weight-based and targets are extrapolated from adult data because dedicated pediatric heart failure RCTs are scarce. A Cochrane review of beta-blockers in pediatric heart failure (2016, 7 trials, N=498) found a trend toward improved left ventricular ejection fraction but was underpowered to confirm mortality benefit [17].

Novel Agents: PCSK9 Inhibitors and SGLT2 Inhibitors

Evolocumab and alirocumab (PCSK9 inhibitors) are approved for adults with established CVD who cannot achieve LDL-C goals on maximally tolerated statins. FOURIER (N=27,564) showed evolocumab reduced LDL-C by 59% and major adverse cardiovascular events by 15% over 2.2 years [18].

SGLT2 inhibitors (empagliflozin, dapagliflozin) now carry Class IIa recommendations in adults with CVD and type 2 diabetes or heart failure with reduced ejection fraction. EMPA-REG OUTCOME (N=7,020) showed empagliflozin 10 mg reduced cardiovascular death by 38% versus placebo [19].

Neither PCSK9 inhibitors nor SGLT2 inhibitors carry FDA approval for established CVD in pediatric populations as of early 2025.

Surgical and Interventional Approaches

Surgical and catheter-based interventions are often the primary treatment for children with established CVD, whereas pharmacotherapy takes precedence in adults until revascularization thresholds are met.

Pediatric Surgical Repair

Neonates with transposition of the great arteries undergo the arterial switch operation within the first 2 weeks of life, with survival exceeding 95% at experienced centers. Children with tetralogy of Fallot undergo complete intracardiac repair at 3 to 6 months of age in most North American centers. Outcomes for complex biventricular repair have improved dramatically: 30-year survival after tetralogy repair now exceeds 85% [20].

Cardiopulmonary bypass physiology differs in neonates versus adults. Neonates require deep hypothermic circulatory arrest at 18 degrees Celsius, with neurological protection and cerebral perfusion strategies tailored to immature brain vasculature.

Percutaneous Coronary Intervention in Adults

For adults with stable ischemic heart disease and one or two vessel CAD, PCI reduces angina but does not reduce mortality compared with optimal medical therapy alone, as confirmed by the ISCHEMIA trial (N=5,179, median follow-up 3.2 years) [21]. In STEMI, primary PCI within 90 minutes of first medical contact is the standard of care, reducing 30-day mortality by approximately 25% compared with thrombolysis [22].

Transcatheter aortic valve replacement (TAVR) has replaced surgical aortic valve replacement as the preferred approach in adults over age 65 with severe aortic stenosis across all surgical risk categories, based on results from PARTNER 3 and Evolut Low-Risk trials [23].

Adult Congenital Heart Disease: The Bridge Population

Over 1.4 million adults in the United States now live with adult congenital heart disease (ACHD), a population that did not exist in large numbers 50 years ago because most complex CHD was fatal in infancy. These patients require lifelong cardiology follow-up from ACHD-specialized centers.

ACHD patients face risks that fall between the pediatric and adult paradigms: their underlying anatomy is congenital, but their acquired complications (arrhythmia, heart failure, pulmonary hypertension, endocarditis) mirror adult disease patterns. The ACC/AHA 2018 ACHD guidelines recommend that all patients with moderate-to-complex ACHD be followed at a regional ACHD center at least every 12 to 24 months [24].

A practical clinical framework for stratifying ACHD patients uses three tiers based on anatomic complexity and residual hemodynamic burden. Tier 1 (simple: small VSD, mild PS) requires primary care-level monitoring with cardiology review every 3 to 5 years. Tier 2 (moderate: repaired tetralogy of Fallot, coarctation repair) requires dedicated ACHD follow-up every 12 to 24 months including cardiac MRI for ventricular volumes. Tier 3 (complex: Fontan circulation, TGA with systemic right ventricle) requires ACHD center follow-up every 6 to 12 months with multidisciplinary team involvement including electrophysiology, heart failure, and reproductive medicine specialists.

Risk Factor Management Across the Lifespan

Pediatric Risk Factor Intervention

The NHLBI Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents (2011) recommend universal lipid screening between ages 9 and 11 and again at ages 17 to 21 [25]. Blood pressure percentile tables adjusted for age, sex, and height define hypertension in children (consistently above the 95th percentile on repeated measurements), a definition completely different from the adult threshold of 130/80 mmHg.

Obesity in childhood accelerates atherosclerosis. The Bogalusa Heart Study showed that obese children had 2.4-fold greater coronary artery fatty streak burden at autopsy compared with lean peers [2].

Adult Risk Factor Targets

Adults with established CVD target LDL-C below 70 mg/dL (below 55 mg/dL in very high-risk patients per ESC 2021 guidelines), blood pressure below 130/80 mmHg, and HbA1c below 7.0% if diabetic [12]. Smoking cessation, physical activity of at least 150 minutes per week of moderate-intensity exercise, and Mediterranean-pattern diet are Class I lifestyle recommendations.

The COURAGE trial (N=2,287) confirmed that optimal medical therapy alone controlled symptoms in 74% of adults with stable CAD over 4.6 years, underscoring the power of pharmacological risk factor modification [26].

Prognosis and Long-Term Outcomes

Children with repaired CHD have substantially improved survival compared with historical cohorts, but they carry a lifelong residual risk for arrhythmia, ventricular dysfunction, and reoperation that requires structured surveillance. A 2020 population-based cohort study from Canada (N=10,657 patients with CHD) found that CHD patients had a 2.6-fold higher rate of premature death compared with age-matched controls even after successful surgical repair [20].

Adults with established atherosclerotic CVD who achieve guideline-directed medical therapy targets have 10-year major adverse cardiovascular event rates below 10% in contemporary registries. Adults who do not achieve LDL-C targets carry significantly higher residual risk: each 10 mg/dL increase in LDL-C above goal is associated with an approximately 5% increase in cardiovascular event rate [13].

Survival after STEMI has improved markedly. Thirty-day mortality after primary PCI for STEMI in the U.S. Fell from approximately 10% in 1995 to under 5% by 2015, driven by rapid door-to-balloon protocols and dual antiplatelet therapy [22].